{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:00:13Z","timestamp":1792047613684,"version":"4.4.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic graft-versus-host disease (cGVHD) is a major limitation to the long-term success of allogeneic hematopoietic cell transplantation (HCT). Our prior study of acute GVHD (aGVHD) defined distinct treatment-response groups based on the response to first-line corticosteroids: steroid-sensitive (SS), steroid-resistant (SR), and steroid-dependent (SD) aGVHDs. We conducted a retrospective, single-institution, cohort study to assess the incidence, risk factors, and clinical outcomes of patients with cGVHD after a previous diagnosis of SS, SD, or SR aGVHD, compared with those with no history of aGVHD. Among 784 consecutive adult and pediatric recipients of HCT for hematologic malignancies between 2008 and 2016, 347 (44%) developed aGVHD, with 13% SS, 12% SD, and 19% SR aGVHD. The 3-year cumulative incidence of cGVHD was 25%. Among those with cGVHD, 39% had no prior aGVHD diagnosis, whereas among those with a prior aGVHD diagnosis, 16% had SS, 24% had SD, and 21% had SR aGVHD. Mild or moderate cGVHD was highest among those with preceding SD aGVHD, whereas severe cGVHD was most frequent among those with previous SR aGVHD. We identified SD and SR aGVHDs as significant independent risk factors for the development of cGVHD after allogeneic HCT, whereas SS aGVHD was not a risk factor. Our study demonstrates that cGVHD after SD aGVHD did not have an intermediate prognosis between SR and SS groups as hypothesized; rather, cGVHD after both SD and SR aGVHD have similar prognoses. Our findings suggest that previous aGVHD response states are important predictors of cGVHD severity and outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009505","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T18:54:18Z","timestamp":1681152858000},"page":"3644-3650","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5641-1285","authenticated-orcid":false,"given":"Shannon","family":"Herzog","sequence":"first","affiliation":[{"name":"1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[{"name":"3Biostatistics Core, University of Minnesota Masonic Cancer Center, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Rayes","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"},{"name":"4Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-341X","authenticated-orcid":false,"given":"Jo-Anne","family":"Young","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"},{"name":"4Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"2Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"issue":"3","key":"2023072117302843100_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023072117302843100_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2023072117302843100_bib3","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023072117302843100_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023072117302843100_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A\u00a0refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023072117302843100_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023072117302843100_bib7","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/bloodadvances.2020003937","article-title":"Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes","volume":"5","author":"El Jurdi","year":"2021","journal-title":"Blood Adv"},{"issue":"23","key":"2023072117302843100_bib8","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2023072117302843100_bib9","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"282","key":"2023072117302843100_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"8","key":"2023072117302843100_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"issue":"446","key":"2023072117302843100_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"2023072117302843100_bib13","author":"Harrell","year":"2015","edition":"2nd ed."},{"issue":"4","key":"2023072117302843100_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","article-title":"Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians","volume":"55","author":"Gauthier","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023072117302843100_bib15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bbmt.2015.12.026","article-title":"Content validity of the Lee chronic graft-versus-host disease symptom scale as assessed by cognitive interviews","volume":"22","author":"Merkel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023072117302843100_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.12659\/AOT.915330","article-title":"Risk factors for transplant outcomes in children and adolescents with non-malignant diseases following allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Zaucha-Pra\u017cmo","year":"2019","journal-title":"Ann Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3644\/2065358\/blooda_adv-2022-009505-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3644\/2065358\/blooda_adv-2022-009505-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T18:10:40Z","timestamp":1689963040000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3644\/495278\/Chronic-GVHD-after-steroid-sensitive-dependent-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":16,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009505","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}